Pierre Fargeot
Institut Jules Bordet
46 Papers
468 Citations
Pierre Fargeot is an academic researcher from Institut Jules Bordet. The author has contributed to research in topics: Breast cancer & Chemotherapy. The author has an hindex of 22, co-authored 46 publications.
Chat about Author
Papers
Epirubicin Increases Long-Term Survival in Adjuvant Chemotherapy of Patients With Poor-Prognosis, Node-Positive, Early Breast Cancer: 10-Year Follow-Up Results of the French Adjuvant Study Group 05 Randomized Trial
Jacques Bonneterre,Henri Roché,Pierre Kerbrat,Alain Brémond,Pierre Fumoleau,Moïse Namer,Marie-Josèphe Goudier,Simon Schraub,Pierre Fargeot,Isabelle Chapelle-Marcillac +9 more
TL;DR: Treatment with adjuvant FEC 100 demonstrated superior DFS and OS versus FEC 50 at 10 years of follow-up, and was not offset by long-term complications such as cardiac toxicity and second malignancy.
289
Randomized Trial Comparing Six Versus Three Cycles of Epirubicin-Based Adjuvant Chemotherapy in Premenopausal, Node-Positive Breast Cancer Patients: 10-Year Follow-Up Results of the French Adjuvant Study Group 01 Trial
Pierre Fumoleau,Pierre Kerbrat,Pascale Romestaing,Pierre Fargeot,Alain Brémond,Moïse Namer,Simon Schraub,Marie-Jo Goudier,Jeanne Mihura,A. Monnier,Pierre Clavere,Daniel Serin,Philippe Seffert,Christiane Pourny,Thomas Facchini,Jean-Philippe Jacquin,Jean-François Sztermer,Jean Datchary,René Ramos,Elisabeth Luporsi +19 more
TL;DR: After a long-term follow-up in an adjuvant setting, the benefit of six cycles of FEC 50 compared with three cycles, whatever the dose, is highly significant in terms of DFS.
107
Long-Term Cardiac Follow-Up in Relapse-Free Patients After Six Courses of Fluorouracil, Epirubicin, and Cyclophosphamide, With Either 50 or 100 mg of Epirubicin, As Adjuvant Therapy for Node-Positive Breast Cancer: French Adjuvant Study Group
Jacques Bonneterre,Henri Roché,Pierre Kerbrat,Pierre Fumoleau,Marie-Josèphe Goudier,Pierre Fargeot,Philippe Montcuquet,Pierre Clavere,Jean-Claude Barats,A. Monnier,Corinne Veyret,Jean Datchary,Isabelle Van Praagh,Isabelle Chapelle-Marcillac +13 more
TL;DR: In the majority of women with primary breast cancer, the benefits of treatment with FEC 100 in terms of disease-free and overall survival outweigh the risks, and cardiac risk factors should be carefully evaluated in patient selection.
96
Randomized Trial Comparing Bleomycin/Etoposide/Cisplatin With Alternating Cisplatin/Cyclophosphamide/Doxorubicin and Vinblastine/Bleomycin Regimens of Chemotherapy for Patients With Intermediate- and Poor-Risk Metastatic Nonseminomatous Germ Cell Tumors: Genito-Urinary Group of the French Federation of Cancer Centers Trial T93MP
Stéphane Culine,Andrew Kramar,Christine Theodore,Lionel Geoffrois,Christine Chevreau,Pierre Biron,Binh Bui Nguyen,Jean-François Héron,Pierre Kerbrat,A. Caty,Remy Delva,Pierre Fargeot,Karim Fizazi,J. Bouzy,Jean-Pierre Droz +14 more
TL;DR: Because of equivalent efficacy and lesser toxicity, the standard treatment for patients with intermediate- and poor-risk metastatic nonseminomatous germ cell tumors remains four cycles of BEP.
88
M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced carcinoma of the bladder: The french federation of cancer centers experience
Arnaud Boutan-Laroze,M. Mahjoubi,Jean-Pierre Droz,P. Charrot,Pierre Fargeot,Pierre Kerbrat,A. Caty,P.M. Voisin,Marc Spielmann,Annie Rey,B. Giraud +10 more
TL;DR: 70 patients with advanced transitional cell carcinoma of the bladder received methotrexate, vinblastine, doxorubicin and cisplatin and the results confirm that this regimen is effective, with some patients being long-term survivors.
68